Highest-materiality recent filing
Lunai Bioworks lands first defense contract, sues naked short sellers over 81.6% FTD shares
Secured first revenue-generating multi-year defense collaboration via BioSymetrics for chemical threat assessment.
Lunai Bioworks regains Nasdaq minimum bid price compliance; faces 1-year monitoring
Nasdaq confirmed Lunai Bioworks regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
Lunai Bioworks announces 1-for-8 reverse stock split effective May 22, 2026
Reverse split ratio set at 1-for-8; stockholder approval obtained on May 8, 2026.
Stockholders approve reverse stock split at ratio of 1-for-3 to 1-for-30
Proposal 1 (reverse split) approved: 13,571,288 for, 1,153,415 against, 61,177 abstentions.
Lunai Bioworks gets additional Nasdaq delisting notice for MVLS; completes $20M merger
Received Nasdaq staff determination on April 28, 2026 for non-compliance with $35M market value of listed securities (MVLS) rule.
Acquired CNS patent portfolio via merger; issued $20M Series B Preferred Stock (no cash) to Oncotelic (62.5%) and Pelerin (37.5%).
Special Meeting postponed from May 4 to May 8, 2026 at 9:00 a.m. ET; virtual format unchanged.
Lunai Bioworks enters $20M strategic acquisition; exchanges $828K debt for equity
Debt exchange: $828,770.14 principal and interest canceled for 3,909,293 shares at $0.21/share and warrants exercisable at $0.21 through 2036.
Lunai Bioworks furloughs all US & Canada employees; CEO/CFO defer salaries amid cash crunch
All US and Canada employees placed on temporary furlough; will not work or receive compensation during furlough.
Nasdaq Panel grants Lunai Bioworks hearing on delisting; hearing set for March 26, 2026
Delisting notice received Feb 6, 2026 from Nasdaq Staff; hearing request granted Feb 17, 2026.
Lunai Bioworks receives Nasdaq delisting notice; appeals hearing requested
Notice received Feb 6, 2026: bid price closed below $1.00 for 30 consecutive business days through Feb 5, 2026.
Lunai Bioworks enters ATM sales agreement for up to $11.7M common stock offering
Agreement with Dawson James Securities for at-the-market offering of up to $11.7M in common stock.
Lunai Bioworks raises $3.13M via private placement of stock and warrants
Sold 3,133,333 shares at $1.00/share and 1,044,444 three-year warrants exercisable after 60 days to accredited investor.
Lunai Bioworks regains Nasdaq compliance by holding annual meeting before deadline
On July 7, 2025, Nasdaq notified Lunai of non-compliance for failing to hold annual meeting within one year of FY end.
Lunai Bioworks shareholders approve all four proposals at 2025 annual meeting
Elected four directors: Weinstein, McNulty, Calder, Collins with >7M votes each; 1.3M broker non-votes.
Lunai Bioworks receives Nasdaq notice for MVLS non-compliance; has 180 days to cure
MVLS fell below $35M for 30 consecutive business days; compliance deadline is April 27, 2026.
Lunai Bioworks Regains Compliance with Nasdaq Bid Price Rule
On April 14, 2025, Nasdaq notified Lunai of bid price deficiency; resolved as of Oct 15, 2025.
Lunai Bioworks 1-for-10 reverse stock split effective Sept 29; new ticker LNAI
Share consolidation at 1-for-10 ratio begins 12:01 a.m. ET on September 29, 2025.
Dutch court declares Lunai Bioworks subsidiary Gedi Cube B.V. bankrupt; impairment expected
Court of Amsterdam declared Gedi Cube B.V. bankrupt on Sept 2, 2025, after voluntary petition.
Renovaro Inc. changes name to Lunai Bioworks Inc.; ticker remains RENB
Certificate of Amendment filed August 18, 2025; name change effective August 20, 2025.
Renovaro receives Nasdaq non-compliance notice for annual meeting; granted extension to Oct 31, 2025
Received Nasdaq notice on July 7, 2025 for failure to comply with Listing Rule 5620(a) requiring annual shareholder meeting.
Renovaro Chairman Maurice van Tilburg resigns effective Aug 22, 2025
Maurice van Tilburg notified board of resignation as Chairman, effective Aug 22, 2025.
Nasdaq notice on July 7, 2025: company failed to hold annual meeting within 12 months of FY ended June 30, 2024.
Renovaro exchanges $9.7M secured debt for $16.1M convertible notes, converted to 53.6M shares
Exchanged $9.7M in secured promissory notes for $16.1M in convertible notes (65% premium).
Renovaro subsidiary GEDi Cube CEO Maurice van Tilburg resigns; remains on board
Maurice van Tilburg resigned as CEO of GEDi Cube B.V., a wholly-owned indirect subsidiary, effective May 30, 2025.
Renovaro receives Nasdaq deficiency notice for low bid price; 180-day cure period
Notice dated April 14, 2025 for failure to maintain $1 minimum bid price over 30 consecutive business days.
Renovaro completes acquisition of Biosymetrics, issues 15M shares
Consummated merger with Biosymetrics on April 8, 2025; Biosymetrics becomes wholly owned subsidiary.
Renovaro Extends LOI with Predictive Oncology, Acquires Shares for $500,000
Renovaro and Predictive Oncology extended the LOI termination date from February 28, 2025 to March 31, 2025.
Renovaro enters definitive merger with AI-driven Biosymetrics for 15M shares
Renovaro issues 15M unregistered common shares to Biosymetrics stockholders for all outstanding shares; lock-up of CEO shares for 1 year.
Renovaro restates multiple prior financials due to warrant accounting error
Audit Committee determined misstatements in Q3 FY2024, FY2024, and Q1 FY2025 filings over warrant exercises in March 2024.
Renovaro subsidiary GEDi Cube enters amended CEO employment agreement with Maurice van Tilburg
Monthly salary of €22,080 (~$22,806) for van Tilburg as GEDi Cube CEO.
Renovaro appoints Nathen Fuentes as CFO; removes interim CFO Simon Tarsh
Nathen Fuentes, age 42, appointed CFO effective January 6, 2025; previously CFO at Telomir Pharmaceuticals (Sep 2023 – Jun 2024).
Renovaro signs binding LOI to buy Predictive Oncology; preferred stock valued at $3/share
POAI shareholders to receive new Renovaro preferred stock in 1:1 exchange; preferred stock redeemable at $3.00 per share after 18 months.
Renovaro appoints Maurice van Tilburg as CEO of subsidiary GEDi Cube
Maurice van Tilburg, age 53, appointed CEO of GEDi Cube, wholly owned subsidiary of Renovaro, effective Dec 30, 2024.
Renovaro COO Francois Binette resigns effective Nov 22, 2024
Francois Binette PhD tendered resignation as COO on Nov 15, 2024.
Renovaro amends consulting agreement with Interim CFO Simon Tarsh; $25k/month plus options
Simon Tarsh continues as Interim CFO under amended agreement; monthly fee $25,000.
Renovaro assigns committee roles to four directors effective Oct 23, 2024
Maurice van Tilburg appointed to Nominating & Governance and Special Litigation committees.
Renovaro appoints new CEO David Weinstein; multiple board resignations including chairman
David Weinstein (age 64) appointed CEO and board member; base salary $400k, up to $150k bonus, 250k restricted shares, 1.6M stock options.
Renovaro receives Nasdaq deficiency notice for bid price below $1; 180-day cure period
Nasdaq notified Renovaro on Sept 12, 2024 that stock failed minimum $1 bid price for 30 consecutive business days.
Renovaro seeks strategic investors for up to 20% of subsidiary Cube
Board intends to offer up to 20% ownership in RenovaroCube, a wholly owned molecular data science subsidiary.
Renovaro restates Q1 2024 financials due to IPR&D asset impairment error; files lawsuit for fraud
Concluded Q1 2024 financials contained material misstatement in IPR&D asset impairment; assets overstated, net loss understated.
Director Leni Boeren resigns from Renovaro board effective June 27, 2024
Leni Boeren resigned as director and chair of the special litigation committee on June 27, 2024.
Renovaro closes $10M private placement of common stock and warrants at $1.4726/unit
Sold 6,421,256 units (1 share + 1/10 warrant) at $1.4726 each, raising ~$9.45M in cash and debt conversions.
Renovaro signs MoU with Amsterdam UMC to form joint cancer immunotherapy company
Signed MoU to establish Newco in Netherlands for personalized cancer immunotherapy.
Renovaro amends bylaws to update corporate name and officer titles
Board approved Amended and Restated Bylaws effective May 21, 2024.
RenovaroCube unveils Flamingo AI model for early multi-cancer detection via fragmentomics
Flamingo uses ultra-low pass WGS of cfDNA; requires as few as 200,000 fragments per sample.
RenovaroCube to acquire remaining 25% of Cyclomics for 100% ownership in cancer diagnostics
RenovaroCube amends LOI to acquire full 100% ownership of Cyclomics (was 75%).
Renovaro Cube audited: €2.1M net loss post-acquisition, going concern noted
Successor period (Aug 24–Dec 31, 2023) net loss of €2,100,579, no revenue generated.
Renovaro appoints Simon Tarsh as Interim CFO; outgoing CFO Puche departs
Simon Tarsh named Interim CFO effective March 11, 2024; replaces Ms. Puche who leaves after >5 years.
Renovaro receives termination notice for License Agreement covering HIV candidate RENB-HV-01
Weird Science LLC terminated the License Agreement for RENB-HV-01 on March 1, 2024.
On May 30, 2025, Maurice van Tilburg notified Renovaro Inc. (the “Company”) of his intent to resign from the office of Chief Executive Officer of GEDi Cube B.V., a wholly-owned indirect subsidiary of the Company, which resignation was effective May 30, 2025.
In connection with Mr. Fuentes’ appointment as Chief Financial Officer, Simon Tarsh was removed as Interim Chief Financial Officer of the Company.
Effective January 6, 2025, the board of directors (the “ Board ”) of Renovaro Inc. (the “ Company ” or “ Renovaro ”) appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company.
On December 30, 2024, the Board appointed Maurice van Tilburg, age 53, as Chief Executive Officer of GEDi Cube B.V.
On November 15, 2024, Francois Binette PhD, Renovaro Inc.’s Chief Operating Officer, tendered his resignation as Chief Operating Officer, effective November 22, 2024.
On October 11, 2024, Avram Miller resigned as a director on the Board of the Company, effective immediately.
On October 15, 2024, Rene Sindlev resigned as the Chairman of the Board of the Company, effective immediately.
Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined
On October 13, 2024, Gregg Alton the Lead Independent Director on the Board, Jayne McNicol and Carol Brosgart formally advised the Board of the Company that they were resigning from the Board, effective immediately.
Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined
On October 12, 2024, James Sapirstein a member of the Board formally advised the Board of the Company that he was resigning from the Board, effective immediately.
Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined
Max materiality 0.90 · Median 0.60 · Most common event other_material